Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients.
The effect of histamine H2-receptor antagonist (famotidine) on the phosphorus-binding abilities of calcium carbonate and calcium lactate were examined in 13 chronic hemodialysis patients. In seven patients receiving calcium carbonate, famotidine (20 mg/d) was given because of gastroduodenal disorders, and calcium carbonate was replaced with calcium lactate as a phosphorus binder after 4 wk of treatment with famotidine. With the 4-wk administration of famotidine accompanied by calcium carbonate, the serum phosphorus level increased from 6.3+/-0.9 to 7.1+/-0.5 mg/dl (P<0.05). However, with the substitution of calcium lactate, the serum phosphorus level decreased significantly when compared to that before substitution (6.3+/-0.2 and 6.0+/-0.9 mg/dl after 4 and 8 wk of substitution, respectively), despite continued administration of famotidine. Serum calcium, creatinine, alkaline phosphatase, high sensitive parathyroid hormone, blood urea nitrogen, arterial blood pH, and bicarbonate were not significantly altered during the trial period. In six control patients treated with calcium carbonate alone, there were no statistical changes in serum calcium and phosphorus levels after substitution of calcium lactate for calcium carbonate. These results suggest that famotidine significantly affects the phosphorus-binding ability of calcium carbonate, but not that of calcium lactate. A careful observation of changes in the serum phosphorus level should be required in hemodialysis patients receiving calcium carbonate and histamine H2-receptor antagonists. Calcium lactate may be useful as a phosphorus binder in such hemodialysis patients.
Takahashi
N
N
Second Department of Internal Medicine, Kagawa Medical University, Japan. ntaka@kms.ac.jp
Shoji
T
T
Matsubara
K
K
Hitomi
H
H
Hashimoto
M
M
Kiyomoto
H
H
Uchida
K
K
Miki
S
S
Hirohata
M
M
Ishizu
T
T
Akiyama
K
K
Mizushige
K
K
Matsuo
H
H
Yuasa
S
S
D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000378:metabolism* / Q000627:therapeutic use; D017610:Calcium Compounds / Q000378:metabolism* / Q000627:therapeutic use; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007773:Lactates / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010758:Phosphorus / Q000097:blood / Q000378:metabolism*; D011446:Prospective Studies; D006435:Renal Dialysis
D017610:Calcium Compounds; D006635:Histamine H2 Antagonists; D007773:Lactates; D010758:Phosphorus; C110051:calcium lactate; D015738:Famotidine; D002119:Calcium Carbonate; D002118:Calcium